Trials Sponsors Conditions Drugs Pricing

Conditions

Human Papillomavirus Vaccines

Outcome Measures

Primary Outcomes (1)

Anti-HPV seropositivity
Seropositivity to 9 HPV types included in Gardasil-9 vaccine will be assessed.
One month post vaccine administration.

Secondary Outcomes (1)

HPV antibody titers
One month post vaccine administration

Study Arms (1)

Gardasil and Gardasil-9

EXPERIMENTAL

Biological: Gardasil and Gardasil-9

Interventions

Gardasil and Gardasil-9Biological

All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.

Gardasil and Gardasil-9

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age12 Years - 18 Years

Sexfemale(Gender-based eligibility)

Gender Eligibility DetailsBased on self-representation of gender identity

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Laval University
Otherlead
Centers for Disease Control and Prevention
US federal agencycollaborator

Study Sites (1)

Laval University Research Hospital Center

Québec, G1E7G9, Canada

Related Publications (2)

Guzun N, Ouakki M, Panicker G, Ionescu IG, Mayrand MH, Unger ER, Sauvageau C. Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years. Vaccine. 2025 Aug 30;62:127475. doi: 10.1016/j.vaccine.2025.127475. Epub 2025 Jul 14.
PMID: 40664165DERIVED
Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials. Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3.
PMID: 31017850DERIVED

MeSH Terms

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Intervention Hierarchy (Ancestors)

Vaccines, CombinedVaccinesBiological ProductsComplex MixturesPapillomavirus VaccinesViral Vaccines

Study Officials

Gaston DeSerres, MD, PhD
Quebec Public Health Institute
STUDY CHAIR

Enrollment

32 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NA
Masking: NONE
Purpose: PREVENTION
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Medical Epidemiologist

Study Record Dates

First Submitted

January 26, 2018

First Posted

February 13, 2018

Study Start

October 1, 2016

Actual (reported)

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Gardasil and Gardasil-9

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

Related Publications (2)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Gardasil and Gardasil-9

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

Related Publications (2)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations